Last reviewed · How we verify
Pneumovax 23- pneumococcal polysaccharide — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Pneumovax 23- pneumococcal polysaccharide (Pneumovax 23- pneumococcal polysaccharide) — Mayo Clinic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pneumovax 23- pneumococcal polysaccharide TARGET | Pneumovax 23- pneumococcal polysaccharide | Mayo Clinic | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pneumovax 23- pneumococcal polysaccharide CI watch — RSS
- Pneumovax 23- pneumococcal polysaccharide CI watch — Atom
- Pneumovax 23- pneumococcal polysaccharide CI watch — JSON
- Pneumovax 23- pneumococcal polysaccharide alone — RSS
Cite this brief
Drug Landscape (2026). Pneumovax 23- pneumococcal polysaccharide — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumovax-23-pneumococcal-polysaccharide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab